<DOC>
	<DOCNO>NCT00627796</DOCNO>
	<brief_summary>Recently , new formulation lanreotide , lanreotide Autogel ( ATG ) 60 mg , 90 mg 120 mg develop order extend duration release active ingredient . The ATG formulation consist solution lanreotide water additional excipients . ATG find linear pharmacokinetics 60 120 mg dos provide prolonged dosing interval good tolerability ( 1 ) . In previous study , ATG demonstrate effective micro-particle lanreotide ( 2,3 ) octreotide-LAR patient acromegaly ( 4-7 ) . Data efficacy ATG newly diagnose patient acromegaly still lack . Similarly , prevalence amount tumor shrinkage ATG treatment unknown . This information particularly useful set first-line therapy acromegaly currently become frequent approach disease ( 8 ) . It demonstrate approximately 80 % patient treat depot somatostatin analogue first line great 20 % tumor shrinkage first 12 month treatment ( 9 ) . A definition significant tumor shrinkage provide 14 study ( include total number patient 424 ) result show 36.6 % ( weighted mean percentage ) patient receive first-line somatostatin analogue therapy acromegaly significant reduction tumor size ( 10 ) . About 50 % patient find great 50 % tumor shrinkage within first year treatment ( 10 ) ; study find percent decrease IGF-I level major determinant tumor shrinkage ( 10 ) . The current open , prospective study design investigate prevalence amount tumor shrinkage newly diagnose patient acromegaly treat first-line ATG .</brief_summary>
	<brief_title>Lanreotide Autogel-120 mg First-Line Treatment Acromegaly</brief_title>
	<detailed_description>This open , prospective , observational , clinical study perform two University Hospitals ( Naples Genova , Italy ) . The primary objective evaluate efficacy ATG 120 mg control GH IGF-I excess acromegaly accord currently accept criterion ( 12 ) tumor shrinkage . The secondary objective assess improvement clinical symptom safety profile . The study population consist least 20 patient , enrol two center Jan 1st 2003 June 30th 2007 . Patients give write informed consent prior enter study . The study perform accord principle define declaration The safety population , define protocol , consist patient receive least one study drug dose . Hormonal evaluation GH level assess mean value 5 sample 30-min interval ( start 08:00 9:00 morning ) take visit injection ATG . IGF-I level assess single sample take visit time first GH sample . All hormonal parameter assess central laboratory ( University Genoa ) . Improvement clinical symptom consider basis semiquantitative scale asthenia , hyperhidrosis , headache , swell extremity , arthralgia , paraesthesia , carpal tunnel syndrome : symptom grade 0 = absent , 1 = mild , 2 = moderate , 3 = severe . Any adverse event ( AE ) study monitor report investigator . Safety , evaluate local laboratory data , assess inclusion final visit : hematology : erythrocyte , leukocyte , platelet , haemoglobin , hematocrit ; biochemistry : glucose , creatinine , alkaline phosphatase , total bilirubin , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , electrolytes ( sodium , potassium , calcium , phosphorous ) glycosylated haemoglobin , triglyceride , total high density lipoprotein ( HDL ) cholesterol , blood amylase , iron , transferrin , prothrombin ; glucose insulin concentration ; hormonal evaluation : thyroid-stimulating hormone ( TSH ) , free triiodothyronine ( FT3 ) , free triiodothyronine ( FT4 ) , follicle stimulate hormone ( FSH ) luteinizing hormone ( LH ) level . Safety related gallbladder assess ultrasound examination perform inclusion end study .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Patients active acromegaly [ serum GH level 2.5 μg/liter and/or 1 μg/liter oral glucose tolerance test ( OGTT ) abnormal IGFI value ] micro ( &lt; 10 mm max tumor diameter ) macroadenoma ( &gt; 10 mm max tumor diameter ) Patients never treat Patients require immediate surgery neurological symptom and/or emergency condition Patients sign informed consent participate study . Patients already treat surgery radiotherapy medical treatment Patients mixed GHPRL adenoma require combine somatostatin dopamine treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>GH</keyword>
	<keyword>IGF-I</keyword>
	<keyword>tumor</keyword>
	<keyword>lanreotide</keyword>
</DOC>